The market that made GLP-1s accessible to millions of Americans is closing — fast.

In early 2025, the FDA declared that compounded semaglutide and tirzepatide were no longer in shortage, triggering a timeline that would force compounding pharmacies out of the GLP-1 business. Telehealth giants like Hims & Hers, which had built significant GLP-1 revenue streams, announced they would wind down compounded offerings. The comment period for the final compounding restrictions closes June 29, 2026 — after which, the window for accessible, lower-cost compounded GLP-1s will effectively shut.

For millions of people who rely on compounded semaglutide or tirzepatide, the question is no longer if their supply changes — it's when, and what happens to their results after.

If you're currently on a GLP-1, this is your most important window. Not to panic. To build a system.

What the Biology Actually Says About Stopping

The science here is unambiguous, and it's not a story about willpower.

The landmark STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), followed participants who had achieved significant weight loss on semaglutide — then stopped the medication. The result: approximately two-thirds of lost weight returned within 12 months of discontinuation.

This isn't failure. This is physiology.

GLP-1 receptor agonists work by modulating appetite signaling, slowing gastric emptying, and influencing how the brain processes hunger and satiety. When the medication is withdrawn, those signals revert. The biological set point that drove hunger before the medication reasserts itself — often aggressively.

What this means practically: the medication is doing more work than most users realize. The reduced appetite, the better portion control, the diminished food noise — much of that is pharmacological. Without a system in place to carry those behaviors forward, the biology wins.

The STEP 1 data isn't a reason to despair. It's a reason to build infrastructure while the medication is still working — when your habits, metabolic markers, and behavioral patterns are at their most favorable.

The Gap Nobody Talks About: Most GLP-1 Users Have No Tracking System

Here's the uncomfortable truth: the majority of people currently on GLP-1 protocols have no structured system for documenting what they're doing or measuring what it's actually accomplishing.

Ask yourself:

Do you know your baseline weight, body fat percentage, or waist circumference from when you started?
Can you articulate your exact protocol — dose timing, compound, escalation history?
Do you have a log of what changed week over week, beyond just the number on the scale?
Do you know your lean mass trends — whether you're losing fat specifically, or also losing muscle?

For most users, the honest answer to most of these questions is no.

This isn't a criticism. The healthcare system didn't build the infrastructure for this. Most prescribers hand over a dosing schedule and a follow-up appointment. Telehealth platforms optimized for access, not longitudinal tracking. You got the medication — but you didn't get the system.

That gap is why results tend to evaporate after discontinuation. Not because the medication failed, but because the behavioral and metabolic scaffolding was never built.

The people who maintain results after stopping GLP-1s share a common trait: they know their numbers, they built sustainable habits during the protocol, and they have a clear picture of where they started versus where they are now. That clarity only comes from tracking.

What Track Your Stack Is Built to Do

PeptidesGPT's new Track Your Stack feature was designed specifically for this moment — for existing GLP-1 users who want to protect what they've built.

Here's what it lets you do:

Log your protocol. Document exactly what you're taking, when you started, how your protocol has evolved, and where you are now. This creates a durable record — something you can bring to a licensed healthcare provider, use as a reference if your access changes, or revisit when evaluating what's working.

Track progress metrics that actually matter. Weight alone is a poor proxy for what GLP-1s are doing. Track Your Stack lets you log the metrics that give you a real picture: body weight over time, energy levels, appetite patterns, and other markers you choose to monitor. Over weeks and months, this builds a personalized dataset — your own N=1 evidence base.

Build the behavioral layer. The behavioral infrastructure is what persists after medication ends. When you're logging consistently, you're forced to pay attention — to what you're eating, how you're moving, what's changing. That attention is itself a habit-forming mechanism. Users who track tend to make better decisions, catch backslides earlier, and course-correct more effectively.

Create continuity across access changes. If your supply of compounded GLP-1 is disrupted — whether by the FDA timeline, a pharmacy change, or cost barriers — your logged history gives you something concrete to work with. A healthcare provider can review a structured protocol log in a way they simply cannot review a vague memory of "I've been on it for about eight months."

This is not a replacement for medical care. Every decision about your protocol — what to take, at what level, for how long — should involve a licensed healthcare provider. Track Your Stack is the system that makes those conversations more informed and more productive.

The Window Is Now

If you're currently on a GLP-1, you are in the best possible position to build this system: the medication is working, your habits are at their most tractable, and you have time before any access disruption forces the question.

Waiting until your supply is disrupted to start tracking is like waiting until a storm hits to build a shelter. The groundwork — your baseline data, your protocol log, your behavioral patterns — needs to exist before the transition, not after.

The June 29 comment deadline is a clock, not a death sentence. Branded GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) will remain available through traditional prescribing channels. But the cost and access landscape will look different. The people who navigate that transition best will be the ones who enter it with a system.

Track Your Stack is live now at peptidesgpt.com.

Log your protocol. Track your metrics. Build the infrastructure that holds your results — whatever happens next.

→ Start tracking at peptidesgpt.com

Disclaimer

This content is produced by PeptidesGPT for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. No information on this platform should be interpreted as a recommendation to start, stop, or modify any medication or health protocol. The Track Your Stack feature is an informational logging tool and is not a medical device. Always consult with a qualified, licensed healthcare provider before making any changes to your health regimen. The STEP 1 trial data cited (Wilding et al., NEJM 2021) is referenced for educational context and does not imply that any outcome described is typical or guaranteed for any individual. Individual results vary.